Patents by Inventor Urvashi Hooda Dhingra

Urvashi Hooda Dhingra has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20030139373
    Abstract: Disclosed are compositions and a method of treating a patient suffering from cancer. The method comprises administering to a patient over a period of up to about 15 days a first component and a second component. The first component consists of a pharmaceutical composition containing as an active ingredient a compound of formula I or a pharmaceutically acceptable salt or ester of said compound. The second component consists of an injection solution containing as an active ingredient gemcitabine. The amount of each component in the combination is such that the combination is therapeutically effective. The components are administered concomitantly or sequentially in a three week to four week treatment cycle for as long as the tumor remains under control and the patient tolerates the regimen. The compositions comprise an antineoplastic combination of a compound for formula I and gemcitabine.
    Type: Application
    Filed: November 8, 2002
    Publication date: July 24, 2003
    Inventors: Lars Holger Breimer, Kapil Dhingra, Urvashi Hooda Dhingra, Steve Ritland
  • Patent number: 6548531
    Abstract: Disclosed is a method of treating a patient suffering from cancer. The method comprises administering to a patient over a period of up to about 15 days a first component and a second component. The first component consists of a pharmaceutical composition containing as an active ingredient a compound of formula I or a pharmaceutically acceptable salt or ester of said compound. The second component consists of an injection solution containing as an active ingredient paclitaxel. The amount of each component in the combination is such that the combination is therapeutically effective. The components are administered concomitantly or sequentially in a three week to four week treatment cycle for as long as the tumor remains under control and the patient tolerates the regimen.
    Type: Grant
    Filed: January 23, 2002
    Date of Patent: April 15, 2003
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Lars Holger Breimer, Kapil Dhingra, Urvashi Hooda Dhingra, Steve Ritland
  • Publication number: 20030013752
    Abstract: A method of treating a patient suffering from cancer comprising administering to the patient a compound of formula I or a therapeutically effective salt or ester thereof, in an amount from about 140 mg/m2/day to about 400 mg/m2/day for an administration period of up to about 14 days, said administration period starting on the first day of a 21-28 day treatment cycle, said treatment cycle being repeated three to four weeks for as long as the tumor remains under control and the regimen is clinically tolerated.
    Type: Application
    Filed: June 12, 2002
    Publication date: January 16, 2003
    Inventors: Lars Holger Breimer, Kapil Dhingra, Urvashi Hooda Dhingra, Steve Ritland
  • Publication number: 20020156118
    Abstract: Disclosed is a method of treating a patient suffering from cancer. The method comprises administering to a patient over a period of up to about 15 days a first component and a second component. The first component consists of a pharmaceutical composition containing as an active ingredient a compound of formula I or a pharmaceutically acceptable salt or ester of said compound. The second component consists of an injection solution containing as an active ingredient paclitaxel. The amount of each component in the combination is such that the combination is therapeutically effective. The components are administered concomitantly or sequentially in a three week to four week treatment cycle for as long as the tumor remains under control and the patient tolerates the regimen.
    Type: Application
    Filed: January 23, 2002
    Publication date: October 24, 2002
    Inventors: Lars Holger Breimer, Kapil Dhingra, Urvashi Hooda Dhingra, Steve Ritland
  • Patent number: 6228877
    Abstract: Compounds of the formula wherein R1 and R1′ are independently alkyl, aryl, alkenyl or alkynyl; R2 and R2′ are independently hydrogen, alkyl, aralkyl, alkoxyalkyl, hydroxyalkyl, haloalkyl, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl, acylaminoalkyl, alkylsulphonylaminoalkyl, arylsulphonyl-aminoalkyl, mercaptoalkyl, alkylthioalkyl, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, alkylthio or alkylsulphinyl; R4, R5, R6, R7, R4′, R5′, R6′, and R7′ each independently are hydrogen, CO2R9, CH2OR10, CHO, CH2NR11R12, CON(R13)2, halogen, cyano, aryl, alkyl, hydroxy, alkoxy, aryloxy, haloalkyl, nitro, amino, aralkyloxy, acylamino, monoalkylamino, dialkylamino, thio, alkyl, alkylsulphinyl, alkylsulphonyl, arylsulphinyl, azide, phosphate or phosphonate provided that at least one of R4, R5, R6 and R7 and at least one of R4′, R5′, R6′, and R7′ are other than hydrogen, with the proviso that when R6 is methoxy, R5
    Type: Grant
    Filed: December 22, 1998
    Date of Patent: May 8, 2001
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Urvashi Hooda Dhingra, Donna Mary Huryn, Dennis Dalton Keith
  • Patent number: 6048887
    Abstract: Certain substituted pyrroles are antiproliferative agents useful in the treatment of cancer.
    Type: Grant
    Filed: March 16, 1999
    Date of Patent: April 11, 2000
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Urvashi Hooda Dhingra, Donna Mary Huryn, June Ke, Giuseppe Federico Weber
  • Patent number: 5891901
    Abstract: Compounds of the formula ##STR1## wherein R is alkyl, alkylthio or hydroxy, as well as, pharmaceutically acceptable salts of compounds of formula I are antiproliferative agents useful in the treatment of cancer.
    Type: Grant
    Filed: July 24, 1997
    Date of Patent: April 6, 1999
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Urvashi Hooda Dhingra, Donna Mary Huryn, Dennis Dalton Keith, Giuseppe Federico Weber
  • Patent number: 5811420
    Abstract: Compounds of formula (I), ##STR1## wherein R.sup.1 and R.sup.2 are independently hydrogen, unsubstituted lower alkyl or lower alkyl substituted by lower alkoxy or lower alkyl thio, or acyl which is unsubstituted or substituted by one or more of lower alkyl, lower alkyl substituted by halogen, and lower alkoxy;X is CO or CHOH;Y is CO or CH.sub.2 ; andZ is O or NH, and epimers and enantiomers thereof,or the physiologically usable salts thereof are useful as anti-tumor agents. They can be prepared by fermentation of Aspergillus sp. and, optionally, subsequent modification of functional groups.
    Type: Grant
    Filed: June 6, 1997
    Date of Patent: September 22, 1998
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Urvashi Hooda Dhingra, Haruyoshi Shirai, Yuki Takehana, Peter Michael Wovkulich, Nami Yabuki